Browsing category:

Gastrointestinal Agent


The recent FDA approval for AstraZeneca’s Nexium 24 hour, or Esomeprazole, was exciting news for the pharmaceutical world. With over sixty million Americans suffering from heartburn at least once a month the advent of a 24 hour treatment that is easy to access is relieving. As an OTC or over the counter treatment for gastroesophageal[…]

Read More

Famotidine, CAS number 76824-35-6, is an effective, tolerable and well- studied treatment for patients with both peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Schwarz Pharma holds the patent for this cogent medication, as the brand name Fluxid, with an expiration due on April 9, 2018.  As an H2 receptor, or histamine blocker receptor,[…]

Read More

Octreotide Acetate is known as the brand name Sandostatin, which is marketed by Novartis. With the patent for sandostatin expiring on May 18, 2015, the opportunities are wide open for researchers seeking to develop a generic form of this number one prescribed somatostatin analogue in the world. Octreotide acetate is a man-made protein which is similar[…]

Read More

Histamine-2 blockers are commonly prescribed for patients with gastroesophageal reflux disease, also known as GERD. Famotidine is an effectual treatment and histamine-2 blocker used to treat many of these patients, also known by the household names Pepcid, Pepcid AC and Mylanta. With the patent for Pepcid AC geltabs expiring on December 29. 2015, researchers are[…]

Read More

Patients suffering from Gastroesophageal Reflux Disease (GERD), benefit greatly from esomeprazole. Also known as Prilosec I.V. in the United States, AstraZeneca will see their patent of this breakout drug expire in May of 2014. The International Foundation for Functional Gastrointestinal Disorders recently reported that health professionals from the American Gastroenterological Association estimate that 33 percent[…]

Read More